Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives.
Voskamp, Marije J
van Daalen, Kim R
Ten Broeke, Toine
MetadataShow full item record
Voskamp, M. J., Li, S., van Daalen, K. R., Crnko, S., Ten Broeke, T., & Bovenschen, N. (2021). Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives.. Cancers (Basel), 13 (21) https://doi.org/10.3390/cancers13215387
Medulloblastoma (MB), a primary tumor of the central nervous system, is among the most prevalent pediatric neoplasms. The median age of diagnosis is six. Conventional therapies include surgical resection of the tumor with subsequent radiation and chemotherapy. However, these therapies often cause severe brain damage, and still, approximately 75% of pediatric patients relapse within a few years. Because the conventional therapies cause such severe damage, especially in the pediatric developing brain, there is an urgent need for better treatment strategies such as immunotherapy, which over the years has gained accumulating interest. Cancer immunotherapy aims to enhance the body's own immune response to tumors and is already widely used in the clinic, e.g., in the treatment of melanoma and lung cancer. However, little is known about the possible application of immunotherapy in brain cancer. In this review, we will provide an overview of the current consensus on MB classification and the state of in vitro, in vivo, and clinical research concerning immunotherapy in MB. Based on existing evidence, we will especially focus on immune checkpoint inhibition and CAR T-cell therapy. Additionally, we will discuss challenges associated with these immunotherapies and relevant strategies to overcome those.
immune checkpoint, immunotherapy, medulloblastoma
External DOI: https://doi.org/10.3390/cancers13215387
This record's URL: https://www.repository.cam.ac.uk/handle/1810/330030
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com